Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Hexarelin vs Lonapegsomatropin (Skytrofa)
An educational, source-based comparison of Hexarelin and Lonapegsomatropin (Skytrofa) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
Side-effect & safety grid
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Hexarelin vs Lonapegsomatropin (Skytrofa) — Key differences
- Class: Hexarelin is classified as Growth Hormone Axis · Cardiac, while Lonapegsomatropin (Skytrofa) is GH Analog · Endocrine.
- Primary research focus: Hexarelin — gh release; Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency.
- Tag: Growth hormone vs FDA-Approved · Endocrine.